Trial Outcomes & Findings for Hormones and Social Anxiety Disorder Treatment (NCT NCT02482805)

NCT ID: NCT02482805

Last Updated: 2017-11-24

Results Overview

Liebowitz Social Anxiety Scale (LSAS)-Performance Subscale at pre- and 1-week post-treatment. The Liebowitz Social Anxiety Scale (LSAS) - Performance Subscale is a subscale of a common measure of social anxiety symptom severity. This subscale consists of only 13 (of the total 24) items related to performance situations. Participants rate both their fear (0 to 3) and avoidance (0 to 3) of these 13 situations, where higher scores indicate worse social anxiety severity. The minimum possible score on this subscale is 0 and the maximum possible score is 78.

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

73 participants

Primary outcome timeframe

Scores at 1 week post-treatment

Results posted on

2017-11-24

Participant Flow

Participant milestones

Participant milestones
Measure
Power Posing
Individuals hold two, 1-minute postures associated with dominance and high power prior to exposure therapy. Cognitive Behavioral Therapy: Exposure therapy for social anxiety disorder
Submissive Posing
Individuals hold two, 1-minute postures associated with submissiveness and low power prior to exposure therapy. Cognitive Behavioral Therapy: Exposure therapy for social anxiety disorder
Rest
Individuals rest (no postures) for 2 minutes prior to exposure therapy. Cognitive Behavioral Therapy: Exposure therapy for social anxiety disorder
Overall Study
STARTED
26
27
20
Overall Study
COMPLETED
22
23
20
Overall Study
NOT COMPLETED
4
4
0

Reasons for withdrawal

Reasons for withdrawal
Measure
Power Posing
Individuals hold two, 1-minute postures associated with dominance and high power prior to exposure therapy. Cognitive Behavioral Therapy: Exposure therapy for social anxiety disorder
Submissive Posing
Individuals hold two, 1-minute postures associated with submissiveness and low power prior to exposure therapy. Cognitive Behavioral Therapy: Exposure therapy for social anxiety disorder
Rest
Individuals rest (no postures) for 2 minutes prior to exposure therapy. Cognitive Behavioral Therapy: Exposure therapy for social anxiety disorder
Overall Study
Lost to Follow-up
4
4
0

Baseline Characteristics

Hormones and Social Anxiety Disorder Treatment

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Power Posing
n=26 Participants
Individuals hold two, 1-minute postures associated with dominance and high power prior to exposure therapy. Cognitive Behavioral Therapy: Exposure therapy for social anxiety disorder
Submissive Posing
n=27 Participants
Individuals hold two, 1-minute postures associated with submissiveness and low power prior to exposure therapy. Cognitive Behavioral Therapy: Exposure therapy for social anxiety disorder
Rest
n=20 Participants
Individuals rest (no postures) for 2 minutes prior to exposure therapy. Cognitive Behavioral Therapy: Exposure therapy for social anxiety disorder
Total
n=73 Participants
Total of all reporting groups
Age, Continuous
26.88 years
STANDARD_DEVIATION 6.99 • n=5 Participants
25.26 years
STANDARD_DEVIATION 8.99 • n=7 Participants
24.60 years
STANDARD_DEVIATION 5.83 • n=5 Participants
25.66 years
STANDARD_DEVIATION 7.48 • n=4 Participants
Sex: Female, Male
Female
18 Participants
n=5 Participants
18 Participants
n=7 Participants
16 Participants
n=5 Participants
52 Participants
n=4 Participants
Sex: Female, Male
Male
8 Participants
n=5 Participants
9 Participants
n=7 Participants
4 Participants
n=5 Participants
21 Participants
n=4 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
5 Participants
n=5 Participants
9 Participants
n=7 Participants
3 Participants
n=5 Participants
17 Participants
n=4 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
20 Participants
n=5 Participants
17 Participants
n=7 Participants
16 Participants
n=5 Participants
53 Participants
n=4 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
1 Participants
n=5 Participants
1 Participants
n=7 Participants
1 Participants
n=5 Participants
3 Participants
n=4 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
0 Participants
n=4 Participants
Race (NIH/OMB)
Asian
6 Participants
n=5 Participants
5 Participants
n=7 Participants
3 Participants
n=5 Participants
14 Participants
n=4 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
0 Participants
n=4 Participants
Race (NIH/OMB)
Black or African American
2 Participants
n=5 Participants
2 Participants
n=7 Participants
3 Participants
n=5 Participants
7 Participants
n=4 Participants
Race (NIH/OMB)
White
14 Participants
n=5 Participants
14 Participants
n=7 Participants
11 Participants
n=5 Participants
39 Participants
n=4 Participants
Race (NIH/OMB)
More than one race
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
0 Participants
n=4 Participants
Race (NIH/OMB)
Unknown or Not Reported
4 Participants
n=5 Participants
6 Participants
n=7 Participants
3 Participants
n=5 Participants
13 Participants
n=4 Participants
Region of Enrollment
United States
26 Participants
n=5 Participants
27 Participants
n=7 Participants
20 Participants
n=5 Participants
73 Participants
n=4 Participants
LSAS-performance
37.96 units on a scale
STANDARD_DEVIATION 14.39 • n=5 Participants
36.19 units on a scale
STANDARD_DEVIATION 10.92 • n=7 Participants
37.85 units on a scale
STANDARD_DEVIATION 10.16 • n=5 Participants
37.27 units on a scale
STANDARD_DEVIATION 11.96 • n=4 Participants
Peak SUDS during exposure
76.31 units on a scale
STANDARD_DEVIATION 14.86 • n=5 Participants
77.74 units on a scale
STANDARD_DEVIATION 15.03 • n=7 Participants
77.50 units on a scale
STANDARD_DEVIATION 11.20 • n=5 Participants
77.16 units on a scale
STANDARD_DEVIATION 13.85 • n=4 Participants

PRIMARY outcome

Timeframe: Scores at 1 week post-treatment

Population: 4 individuals did not complete LSAS at post-treatment; accordingly the analyses were conducted with only 69 individuals (versus the total sample size of 73) who had complete data.

Liebowitz Social Anxiety Scale (LSAS)-Performance Subscale at pre- and 1-week post-treatment. The Liebowitz Social Anxiety Scale (LSAS) - Performance Subscale is a subscale of a common measure of social anxiety symptom severity. This subscale consists of only 13 (of the total 24) items related to performance situations. Participants rate both their fear (0 to 3) and avoidance (0 to 3) of these 13 situations, where higher scores indicate worse social anxiety severity. The minimum possible score on this subscale is 0 and the maximum possible score is 78.

Outcome measures

Outcome measures
Measure
Power Posing
n=23 Participants
Individuals hold two, 1-minute postures associated with dominance and high power prior to exposure therapy. Cognitive Behavioral Therapy: Exposure therapy for social anxiety disorder
Submissive Posing
n=26 Participants
Individuals hold two, 1-minute postures associated with submissiveness and low power prior to exposure therapy. Cognitive Behavioral Therapy: Exposure therapy for social anxiety disorder
Rest
n=20 Participants
Individuals rest (no postures) for 2 minutes prior to exposure therapy. Cognitive Behavioral Therapy: Exposure therapy for social anxiety disorder
LSAS-performance Subscale
34.04 units on a scale
Standard Deviation 14.76
32.54 units on a scale
Standard Deviation 8.74
32.05 units on a scale
Standard Deviation 13.70

PRIMARY outcome

Timeframe: Scores at 1 week post-treatment

Population: 8 individuals did not complete the post-treatment exposure; accordingly the analyses were conducted with only 66 individuals (versus the total sample size of 73) who had complete data.

Peak (max) SUDS ratings (0 to 100 scale) during treatment exposure and 1 week post-treatment exposure. Peak Subjective Units of Distress Scale (SUDS) is the maximum amount of fear experienced rated on a 0 to 100 point scale, where 0 indicates no anxiety and 100 indicates the maximum level of anxiety.

Outcome measures

Outcome measures
Measure
Power Posing
n=23 Participants
Individuals hold two, 1-minute postures associated with dominance and high power prior to exposure therapy. Cognitive Behavioral Therapy: Exposure therapy for social anxiety disorder
Submissive Posing
n=23 Participants
Individuals hold two, 1-minute postures associated with submissiveness and low power prior to exposure therapy. Cognitive Behavioral Therapy: Exposure therapy for social anxiety disorder
Rest
n=20 Participants
Individuals rest (no postures) for 2 minutes prior to exposure therapy. Cognitive Behavioral Therapy: Exposure therapy for social anxiety disorder
Subjective Units of Distress Scale (SUDs)
59.26 units on a scale
Standard Deviation 14.43
59.17 units on a scale
Standard Deviation 23.85
48.75 units on a scale
Standard Deviation 19.79

PRIMARY outcome

Timeframe: Baseline and 20 minutes after posture manipulation

Saliva sample taken before posture manipulation and 20 minutes after. Outcome is the change from pre- to post-manipulation in testosterone levels.

Outcome measures

Outcome measures
Measure
Power Posing
n=26 Participants
Individuals hold two, 1-minute postures associated with dominance and high power prior to exposure therapy. Cognitive Behavioral Therapy: Exposure therapy for social anxiety disorder
Submissive Posing
n=27 Participants
Individuals hold two, 1-minute postures associated with submissiveness and low power prior to exposure therapy. Cognitive Behavioral Therapy: Exposure therapy for social anxiety disorder
Rest
n=20 Participants
Individuals rest (no postures) for 2 minutes prior to exposure therapy. Cognitive Behavioral Therapy: Exposure therapy for social anxiety disorder
Salivary Testosterone Levels
-2.31 pg/mL
Standard Deviation 10.82
-0.88 pg/mL
Standard Deviation 33.31
-1.47 pg/mL
Standard Deviation 54.56

Adverse Events

Power Posing

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Submissive Posing

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Rest

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Michelle Davis

University of Texas at Austin

Phone: 214-470-1371

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place